Understanding Leaky Gut: What the Science Really Says
What Is Leaky Gut?
Leaky gut, scientifically known as increased intestinal permeability, refers to a breakdown in the intestinal barrier that normally separates the gut contents from the bloodstream. The intestinal barrier consists of several protective layers: surface mucus, epithelial cells connected by tight junctions, and immune defenses. When this barrier becomes compromised, it allows unwanted substances—including bacterial components, toxins, and undigested food particles—to pass into the bloodstream.
The Pathophysiology: How Does It Happen?
The intestinal barrier can break down through several mechanisms:
Tight Junction Disruption: The spaces between intestinal cells are normally sealed by protein complexes called tight junctions. When these loosen, the paracellular pathway opens, allowing larger molecules to pass through.
The Zonulin Pathway: Zonulin is a protein that regulates tight junction permeability. Certain triggers (like gluten, bacteria, and stress) can increase zonulin levels, opening the tight junctions.
Epithelial Cell Death: Damage to the intestinal lining cells themselves creates gaps in the barrier.
Gut Dysbiosis: An imbalance in gut bacteria can compromise barrier integrity through multiple pathways, including production of inflammatory compounds and reduction of beneficial metabolites like short-chain fatty acids.
Transcellular Permeability: In some cases, substances can pass directly through damaged epithelial cells rather than between them.
Does Leaky Gut Really Exist? The Evidence
Yes, increased intestinal permeability is a well-documented physiological phenomenon that can be measured through validated scientific methods. Researchers measure intestinal permeability using:
- Oral administration of probe molecules (like lactulose/mannitol tests)
- Blood biomarkers including zonulin, lipopolysaccharide-binding protein (LBP), and intestinal fatty acid-binding protein (I-FABP)
**
-
| Test Name | Why It’s Important | What You Find With Leaky Gut | CPT Code | How to Order on Labcorp |
|---|---|---|---|---|
| Zonulin (Serum) | Regulates tight junction opening; key permeability marker | Elevated zonulin indicating increased intestinal permeability | 83520 | Send-out: "Zonulin, Serum" (not a standard Labcorp in-house test) |
| LPS Antibodies (IgA, IgM, IgG) | Detects immune response to bacterial endotoxin crossing the gut barrier | Elevated IgA/IgM/IgG to LPS | 86140 (per antibody class) | Send-out: "LPS Antibodies Panel" |
| Occludin/Zonulin Antibodies | Identifies immune attack on tight junction proteins | Elevated antibodies to occludin/zonulin | 86255 | Send-out: "Occludin/Zonulin Antibodies" |
| Actomyosin Antibodies | Marker of epithelial cytoskeleton damage | Elevated actomyosin IgA/IgG | 86255 | Send-out: "Actomyosin Antibodies" |
| I-FABP (Intestinal Fatty Acid Binding Protein) | Released when enterocytes are injured | Elevated I-FABP | 83520 | Send-out: "I-FABP" |
| DAO (Diamine Oxidase) | Low DAO indicates mucosal injury and histamine overload | Low DAO levels | 83520 | Send-out: "Diamine Oxidase" |
| IgG Food Antibodies | Indicates antigen translocation through a permeable gut | Multiple elevated IgG food antibodies | 86001 | Send-out: "Food IgG Panel" |
| IgA Food Antibodies | Reflects mucosal immune activation | Elevated IgA food antibodies | 82784 | Send-out: "Food IgA Panel" |
| Candida Antibodies (IgG/IgA/IgM) | Detects fungal translocation or overgrowth | Elevated Candida IgG/IgA/IgM | 86628 | Labcorp 096727: "Candida Antibodies" |
| hs-CRP | Measures systemic inflammation from endotoxin exposure | Elevated hs-CRP | 86141 | Labcorp 120766: "CRP, High Sensitivity" |
| ESR | General inflammation marker | Elevated ESR | 85652 | Labcorp 005215: "Sedimentation Rate" |
| ANA | Detects systemic autoimmune activation | Positive ANA | 86038 | Labcorp 012295: "ANA Screen, IFA" |
| TPO Antibodies | Autoimmune thyroid marker worsened by permeability | Elevated TPO antibodies | 86376 | Labcorp 006676: "Thyroid Peroxidase Antibodies" |
| Tissue Transglutaminase IgA | Detects celiac-related permeability | Elevated tTG-IgA | 83516 | Labcorp 161299: "tTG IgA" |
| Vitamin B12 | Malabsorption marker | Low B12 | 82607 | Labcorp 001503: "Vitamin B12" |
| Iron + Ferritin | Detects malabsorption and inflammation | Low iron, low ferritin | 83540, 82728 | Labcorp 001339: "Iron and TIBC"; 004598: "Ferritin" |
| Vitamin D | Commonly low with mucosal injury | Low 25-OH Vitamin D | 82306 | Labcorp 081950: "Vitamin D, 25-Hydroxy" |
| Magnesium | Malabsorption marker | Low magnesium | 83735 | Labcorp 001537: "Magnesium" |
| Fasting Insulin | Endotoxin-driven metabolic inflammation | Elevated fasting insulin | 83525 | Labcorp 004333: "Insulin" |
| Fasting Glucose | Metabolic stress marker | Elevated glucose | 82947 | Labcorp 001032: "Glucose, Fasting" |
| Triglycerides | Metabolic inflammation marker | Elevated triglycerides | 84478 | Labcorp 001172: "Lipid Panel" |
| Test Name | Pathophysiology | Molecules / Mechanisms Involved |
|---|---|---|
| Zonulin (Serum) | Controls tight junction opening; elevated levels loosen intestinal barrier | ZO-1, occludin, claudins, CXCR3 pathway |
| LPS Antibodies (IgA/IgM/IgG) | Immune response to bacterial endotoxin entering bloodstream | LPS, TLR4 activation, NF-κB pathway |
| Occludin/Zonulin Antibodies | Autoimmune reaction to tight junction proteins | Occludin, zonulin, epithelial tight junction complexes |
| Actomyosin Antibodies | Damage to epithelial cytoskeleton increases permeability | Actin-myosin filaments, epithelial cytoskeleton |
| I-FABP | Released when enterocytes are injured or die | Enterocyte cytosolic proteins, epithelial apoptosis |
| DAO | Produced by intestinal mucosa; low levels indicate mucosal injury | Histamine metabolism, mucosal integrity |
| IgG Food Antibodies | Indicate antigen translocation through a permeable gut | Food antigens, IgG-mediated immune response |
| IgA Food Antibodies | Reflect mucosal immune activation | Secretory IgA, mucosal immunity |
| Candida Antibodies | Indicate fungal overgrowth or translocation | Candida antigens, β-glucans |
| hs-CRP | Systemic inflammation from endotoxin exposure | IL-6, TNF-α, acute phase response |
| ESR | General inflammatory marker | Fibrinogen, rouleaux formation |
| ANA | Autoimmune activation triggered by antigen leakage | Nuclear antigens, loss of immune tolerance |
| TPO Antibodies | Autoimmune thyroid activation worsened by permeability | Thyroid peroxidase, molecular mimicry |
| tTG-IgA | Autoimmune reaction to gluten damaging intestinal lining | Tissue transglutaminase, gliadin peptides |
| Vitamin B12 | Malabsorption from mucosal injury | Intrinsic factor, ileal absorption |
| Iron/Ferritin | Malabsorption and inflammation reduce iron stores | Hepcidin, ferritin, transferrin |
| Vitamin D | Low levels correlate with mucosal inflammation | VDR receptors, immune modulation |
| Magnesium | Malabsorption from epithelial dysfunction | TRPM6/7 channels |
| Fasting Insulin | Endotoxin-driven metabolic inflammation increases insulin resistance | LPS, TLR4, IRS-1 inhibition |
| Triglycerides | Inflammation increases hepatic triglyceride production | VLDL, hepatic lipogenesis |
However, there's an important distinction: while increased intestinal permeability exists and can be measured, the term "leaky gut syndrome" as a distinct disease entity remains controversial in mainstream medicine. The scientific consensus is that increased intestinal permeability is associated with various diseases but whether it's a cause or consequence is still being investigated.
Long-Term Health Consequences
Research has linked increased intestinal permeability to numerous conditions:
Autoimmune Diseases: Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, celiac disease, [systemic lupus erythematosus](/rare-disease/systemic-lupus-erythematosus), Hashimoto's thyroiditis, and Graves' disease
Metabolic Disorders: Obesity, non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
Gastrointestinal Conditions: Inflammatory bowel disease, irritable bowel syndrome
Neurological Conditions: Depression, schizophrenia, chronic fatigue syndrome/myalgic encephalomyelitis
Cancer: Particularly colorectal cancer, with evidence suggesting barrier dysfunction may promote tumor development
Cardiovascular Mortality: Higher levels of intestinal permeability markers predict increased risk of death from coronary artery disease
Sepsis and Infections: Increased bacterial translocation can lead to severe systemic infections
Leaky Gut and Ocular Health
Emerging research has identified a "gut-eye axis" connecting intestinal health to eye diseases:
General Eye Diseases: Studies show associations between gut dysbiosis and uveitis, age-related macular degeneration, glaucoma, and dry eye disease
Meibomian Gland Dysfunction (MGD): While direct studies linking intestinal permeability to MGD are limited, MGD shares inflammatory pathways with conditions known to be associated with leaky gut. The microbiome alterations seen in MGD patients suggest a potential gut-eye connection, though this requires further research.
Ocular Rosacea: Multiple studies demonstrate strong associations between rosacea (including ocular rosacea) and gastrointestinal disorders. Patients with rosacea have significantly higher rates of celiac disease, Crohn's disease, ulcerative colitis, and irritable bowel syndrome. One study found elevated fecal calprotectin (a marker of intestinal inflammation) in rosacea patients without diagnosed GI disease.
[Thyroid Eye Disease](/rare-disease/thyroid-eye-disease) (Graves' Orbitopathy): Groundbreaking research has directly linked increased intestinal permeability to Graves' orbitopathy. Patients with thyroid eye disease show elevated levels of LBP, zonulin, and bacterial translocation markers. These markers correlate with increased inflammation and myofibroblast accumulation in orbital tissue, suggesting that gut barrier dysfunction may aggravate the disease.
Hashimoto's Thyroiditis: Patients show increased zonulin concentrations and gut dysbiosis, suggesting leaky gut may contribute to thyroid autoimmunity.
Leaky Gut and Other Conditions
Cancer: Beyond colorectal cancer, increased intestinal permeability has been implicated in extraintestinal cancers through bacterial translocation and chronic inflammation. Zonulin levels are elevated in colorectal cancer patients and may serve as a biomarker.
Autoimmune Diseases: The relationship is well-established, with leaky gut potentially allowing bacterial antigens to trigger or exacerbate autoimmune responses.
Fibromyalgia: Patients show significantly elevated markers of intestinal barrier dysfunction (anti-beta-lactoglobulin antibodies, zonulin, LPS, and sCD14) compared to healthy controls, with levels correlating to symptom severity.
Chronic Fatigue Syndrome/ME: Similar to fibromyalgia, ME/CFS patients demonstrate increased gut permeability and bacterial translocation, though typically to a lesser degree than fibromyalgia patients.
Early Death: Increased intestinal permeability markers, particularly zonulin and LBP, predict 10-year risk of death from coronary artery disease. In COVID-19, elevated intestinal permeability markers were associated with higher mortality risk.
Is Leaky Gut Reversible?
Yes, evidence suggests that increased intestinal permeability can be reversed, particularly in stress-induced or non-inflammatory conditions. However, an important caveat: while barrier function can be restored, this alone has not been proven to cure diseases associated with leaky gut. The relationship is complex—improving barrier function may help manage symptoms but doesn't necessarily reverse underlying disease processes.
Is Leaky Gut Preventable?
Prevention focuses on avoiding factors that damage the intestinal barrier and promoting factors that strengthen it:
Avoid:
- Excessive alcohol consumption
- Chronic NSAID use
- High-fat diets (especially saturated fats)
- Excessive sugar intake
- Food emulsifiers and additives
- Chronic stress
- Antibiotic overuse
Promote:
- Balanced, Organic diet
- Regular physical activity
- Stress management
- Adequate sleep
- Probiotic-rich foods
Best Foods to Prevent or Reverse Leaky Gut
Foods That Strengthen the Barrier:
| Treatment | Mechanism of Action | Evidence Summary |
|---|---|---|
| L-Glutamine | Primary fuel for enterocytes; repairs mucosal lining | Shown to reduce permeability and improve tight junction integrity |
| Zinc Carnosine | Stabilizes mucosal barrier and reduces inflammation | Clinical trials show improved intestinal healing |
| Probiotics (Lactobacillus, Bifidobacterium) | Restore microbiome balance and reduce LPS | Multiple RCTs show reduced permeability markers |
| Colostrum | Contains growth factors that repair mucosa | Studies show reduced zonulin and improved barrier function |
| Butyrate | Short-chain fatty acid that strengthens tight junctions | Strong evidence for epithelial repair and anti-inflammatory effects |
| Omega-3 Fatty Acids | Reduce inflammation and improve epithelial integrity | Shown to decrease LPS and inflammatory cytokines |
| Vitamin D | Modulates immune response and tight junction proteins | Low levels correlate with permeability; supplementation improves markers |
| Curcumin | Anti-inflammatory; reduces NF-κB activation | Shown to reduce intestinal inflammation and oxidative stress |
| Aloe Vera | Soothes mucosa and reduces inflammation | Evidence supports improved mucosal healing |
| Low-FODMAP or Elimination Diet | Reduces antigen load and inflammation | Improves symptoms and reduces immune activation |
| Intermittent Fasting | Allows mucosal regeneration and reduces endotoxin load | Studies show reduced LPS and improved metabolic markers |
| Stress Reduction (HRV training, meditation) | Reduces cortisol-driven barrier breakdown | Strong evidence linking stress to permeability |
| Sleep Optimization | Improves immune regulation and epithelial repair | Poor sleep increases inflammatory cytokines and permeability |
- Promote production of short-chain fatty acids (especially butyrate), which strengthen tight junctions
Fermented Foods: Yogurt, kefir, sauerkraut, kimchi, miso
- Provide beneficial probiotics that support barrier function
Omega-3 Rich Foods: Fatty fish (salmon, mackerel, sardines), walnuts, flaxseeds, chia seeds
- Reduce inflammation and support epithelial integrity
Polyphenol-Rich Foods: Berries, green tea, dark chocolate, olive oil, colorful vegetables
- Antioxidant and anti-inflammatory properties
Specific Amino Acids:
- Glutamine-rich foods: bone broth, meat, fish, eggs, cabbage, beans
- Methionine and cysteine: eggs, fish, poultry, Brazil nuts
Micronutrient-Rich Foods:
- Vitamin A: sweet potatoes, carrots, leafy greens
- Vitamin D: fatty fish, egg yolks, fortified foods
- Zinc: oysters, beef, pumpkin seeds, lentils
Prebiotics: Garlic, onions, leeks, asparagus, bananas, oats
- Feed beneficial gut bacteria
Foods That May Harm the Barrier:
- High-fat processed foods
- Excessive refined sugars and high-fructose corn syrup
- Alcohol (especially in excess)
- Processed meats
- Food emulsifiers and additives
- For sensitive individuals: gluten (especially in celiac disease or non-celiac gluten sensitivity)
Fastest Ways to Heal Leaky Gut
Based on clinical evidence, a multi-pronged approach works best:
1. Dietary Modifications (Most Important):
- Adopt a whole-food, plant-predominant diet
- Increase fiber intake to 25-35g daily
- Include fermented foods daily
- Eliminate or reduce processed foods, added sugars, and excessive alcohol
- Consider temporary elimination of potential triggers if food sensitivities are suspected
2. Probiotic and Prebiotic Supplementation:
- Meta-analyses show probiotics and synbiotics significantly reduce markers of intestinal permeability (zonulin and LPS)
- Prebiotics alone also show strong effects
- Multi-strain probiotics appear more effective than single strains
3. Specific Nutrients:
- Glutamine supplementation (especially in stress states like burns or intense exercise)
- Zinc supplementation if deficient
- Vitamins A and D
- Omega-3 fatty acids
4. Lifestyle Modifications:
- Stress reduction (meditation, yoga, adequate sleep)
- Regular moderate exercise (but avoid overtraining)
- Avoid unnecessary antibiotics and NSAIDs
5. Address Underlying Conditions:
- Treat any diagnosed GI disorders
- Manage autoimmune conditions
- Control blood sugar in diabetes
Timeline: Improvements in barrier function can occur within weeks to months with consistent intervention, though individual responses vary.
Dr. Gundry's Recommendations and Controversies:
I know Dr. Gundry is very controversial to some people. I once mentioned Dr. Gundry’s name to a PhD in nutrition and she almost had a heart attack. Still, I think he has some valid points and I generally do follow his diet personally.
So for those who do not know: Dr. Steven Gundry, a cardiac surgeon turned diet guru, promotes a "lectin-free" diet in his popular books. His main recommendations include:
Foods to Avoid According to Gundry:
- Lectins (found in legumes, whole grains, nightshade vegetables, and some fruits)
- Conventional dairy
- Most grains (especially those containing gluten)
- Nightshade vegetables (tomatoes, peppers, eggplant, potatoes)
- Many beans and legumes
- Certain nuts and seeds with skins
The Scientific Controversies:
The American Heart Association's 2023 scientific statement on popular dietary patterns does not specifically endorse lectin-avoidance diets. In fact, the evidence-based dietary patterns they recommend include many foods Gundry advises against:
Major Concerns with Gundry's Approach:
1. Contradicts Established Evidence: Whole grains, legumes, and many of the foods Gundry recommends avoiding are consistently associated with reduced cardiovascular disease, diabetes, and mortality in large-scale studies.
2. Lack of Clinical Evidence: There are no published peer-reviewed clinical trials supporting the lectin-free diet for improving health outcomes in the general population.
3. Nutritional Deficiencies: Eliminating entire food groups (legumes, whole grains, many vegetables) risks nutrient deficiencies and loss of beneficial phytochemicals.
4. Overgeneralization: While lectins can be problematic for some individuals with specific conditions, there's no evidence that healthy people need to avoid them.
5. Conflicts of Interest: Dr. Gundry sells supplements and products related to his dietary recommendations, raising questions about potential bias.
What Mainstream Science Says Instead:
Leading medical organizations (American Heart Association, American College of Cardiology, American College of Lifestyle Medicine) consistently recommend:
- Increased consumption of whole grains, legumes, fruits, and vegetables
- Plant-based proteins (including beans and lentils)
- Nuts and seeds
- Whole, minimally processed foods
- Limited processed meats and added sugars
The Bottom Line on Gundry: While some individuals may feel better avoiding certain foods, the broad elimination of nutrient-dense plant foods recommended by Dr. Gundry contradicts the weight of scientific evidence and may do more harm than good for most people.
Practical Recommendations
For most people looking to support intestinal barrier health:
1. Focus on whole, minimally processed foods
2. Eat a diverse, plant-rich diet with plenty of vegetables, fruits, whole grains, legumes, nuts, and seeds
3. Include fermented foods regularly
4. Choose healthy fats from fish, olive oil, nuts, and avocados
5. Limit processed foods, added sugars, and excessive alcohol
6. Consider probiotic supplementation if dietary sources are insufficient
7. Manage stress and prioritize sleep
8. Work with healthcare providers to address any underlying conditions
Remember: While optimizing gut barrier function is important for overall health, it's not a cure-all. If you have concerning symptoms, work with qualified healthcare professionals rather than relying solely on dietary changes or unproven protocols.
Key Findings on Specific Conditions:
Ocular Health: The gut-eye axis is an emerging area of research. While direct evidence linking intestinal permeability to meibomian gland dysfunction is limited, strong associations exist between gut health and various eye conditions.[8][9][10][11] Notably, Graves' orbitopathy (thyroid eye disease) has been directly linked to increased intestinal permeability, with elevated markers correlating to disease severity.[12][13] Ocular rosacea shows strong associations with gastrointestinal disorders, including elevated intestinal inflammation markers.[14][15][16][17]
Other Conditions: Research demonstrates associations between increased intestinal permeability and:
- Cancer: Particularly colorectal cancer, with zonulin serving as a potential biomarker[18][19][20][21]
- Autoimmune diseases: Well-established connections with multiple conditions[22][23][24][25]
- Fibromyalgia and ME/CFS: Significantly elevated barrier dysfunction markers[26][27][28][29]
- Mortality: Intestinal permeability markers predict cardiovascular death risk[30][31]
Dietary Interventions: Evidence supports that intestinal permeability is reversible through dietary and lifestyle modifications.[6][7][1][32] Foods that strengthen the barrier include fiber, fermented foods, omega-3 fatty acids, polyphenols, specific amino acids (glutamine), and micronutrients (vitamins A and D, zinc).[6][33][34][5][35] Probiotics and prebiotics show significant benefits in meta-analyses.[7]
Dr. Gundry Controversy: Dr. Gundry's lectin-free diet recommendations contradict mainstream scientific evidence. The American Heart Association and other leading medical organizations recommend many foods Gundry advises against (whole grains, legumes, nightshade vegetables).[36][37] While it is true there are no peer-reviewed clinical trials supporting the lectin-free diet for general health, and eliminating these nutrient-dense foods may cause more harm than benefit, I tend to personally follow Dr. Gundry‘s diet in general, but I’m careful to recommend it to Patients as a general rule.[37][38]
Important Caveat: While increased intestinal permeability can be measured and improved, it remains unproven that restoring barrier function alone can cure associated diseases. The relationship between leaky gut and disease is complex, and barrier dysfunction may be both cause and consequence.[1][5]
References
1. Leaky Gut: Mechanisms, Measurement and Clinical Implications in Humans. Camilleri M. Gut. 2019;68(8):1516-1526. doi:10.1136/gutjnl-2019-318427.
2. Intestinal Barrier in Human Health and Disease. Di Tommaso N, Gasbarrini A, Ponziani FR. International Journal of Environmental Research and Public Health. 2021;18(23):12836. doi:10.3390/ijerph182312836.
3. Gut Microbiota, Intestinal Permeability, and Systemic Inflammation: A Narrative Review. Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Internal and Emergency Medicine. 2024;19(2):275-293. doi:10.1007/s11739-023-03374-w.
4. Regulation of Intestinal Permeability in Health and Disease: Possible Therapeutic Applications. Güemes-González AM, Arriaga-Pizano LA, Chacón-Salinas R, Wong-Baeza I, Ferat-Osorio E. Archives of Medical Research. 2025;57(3):103321. doi:10.1016/j.arcmed.2025.103321.
5. What Is the Leaky Gut? Clinical Considerations in Humans. Camilleri M. Current Opinion in Clinical Nutrition and Metabolic Care. 2021;24(5):473-482. doi:10.1097/MCO.0000000000000778.
6. Review: Human Intestinal Barrier-Optimal Measurement and Effects of Diet in the Absence of Overt Inflammation or Ulceration. Camilleri M. Alimentary Pharmacology & Therapeutics. 2025;62(2):128-145. doi:10.1111/apt.70225.
7. Reinforcing Gut Integrity: A Systematic Review and Meta-Analysis of Clinical Trials Assessing Probiotics, Synbiotics, and Prebiotics on Intestinal Permeability Markers. Ghorbani Z, Shoaibinobarian N, Noormohammadi M, et al. Pharmacological Research. 2025;216:107780. doi:10.1016/j.phrs.2025.107780.
8. The Gut-Eye Axis: The Retinal/Ocular Degenerative Diseases and the Emergent Therapeutic Strategies. Kammoun S, Rekik M, Dlensi A, et al. Frontiers in Cellular Neuroscience. 2024;18:1468187. doi:10.3389/fncel.2024.1468187.
9. Influence of Gut Microbiota on Eye Diseases: An Overview. Napolitano P, Filippelli M, Davinelli S, et al. Annals of Medicine. 2021;53(1):750-761. doi:10.1080/07853890.2021.1925150.
10. A Review of the Impact of Alterations in Gut Microbiome on the Immunopathogenesis of Ocular Diseases. Bu Y, Chan YK, Wong HL, et al. Journal of Clinical Medicine. 2021;10(20):4694. doi:10.3390/jcm10204694.
11. From Gut to Eye: Exploring the Role of Microbiome Imbalance in Ocular Diseases. Tîrziu AT, Susan M, Susan R, et al. Journal of Clinical Medicine. 2024;13(18):5611. doi:10.3390/jcm13185611.
12. Intestinal Permeability Is Associated With Aggravated Inflammation and Myofibroblast Accumulation in Graves' Orbitopathy: The MicroGO Study. Fenneman AC, van der Spek AH, Hartstra A, et al. Frontiers in Endocrinology. 2023;14:1173481. doi:10.3389/fendo.2023.1173481.
13. Elevated Levels of Circulating Biomarkers Related to Leaky Gut Syndrome and Bacterial Translocation Are Associated With Graves' Disease. Zheng D, Liao H, Chen S, et al. Frontiers in Endocrinology. 2021;12:796212. doi:10.3389/fendo.2021.796212.
14. Rosacea, Germs, and Bowels: A Review on Gastrointestinal Comorbidities and Gut-Skin Axis of Rosacea. Wang FY, Chi CC. Advances in Therapy. 2021;38(3):1415-1424. doi:10.1007/s12325-021-01624-x.
15. Rosacea and Gastrointestinal Disorders: A Population-Based Cohort Study. Egeberg A, Weinstock LB, Thyssen EP, Gislason GH, Thyssen JP. The British Journal of Dermatology. 2017;176(1):100-106. doi:10.1111/bjd.14930.
16. Rosacea and Gastrointestinal Diseases: A Case-Control Study in the All of Us Database. Piontkowski AJ, Sharma D, Ungar B. Dermatology (Basel, Switzerland). 2024;240(5-6):875-878. doi:10.1159/000541469.
17. Evaluation of Fecal Calprotectin as a Marker of Gastrointestinal Inflammation in Rosacea: A Case-Control Study. Aksu Çerman A, Aktaş Karabay E, Kaya HE, et al. Dermatologic Therapy. 2021;34(3):e14946. doi:10.1111/dth.14946.
18. The Barrier-Microbiota-Inflammation Axis in Colorectal Cancer: Mechanisms and Emerging Diagnostic & Therapeutic Strategies. Dong X, Yang J, He L, et al. Cancers. 2026;18(4):576. doi:10.3390/cancers18040576.
19. Serum Zonulin and Colorectal Cancer Risk. Marino M, Mignozzi S, Michels KB, et al. Scientific Reports. 2024;14(1):28171. doi:10.1038/s41598-024-76697-z.
20. Association of Circulating Protein Biomarkers of Gut Barrier Integrity and Inflammation With Colorectal Adenomas and Colorectal Cancers. Ganesan H, Souček P, Liška V, et al. Digestive Diseases and Sciences. 2025;:10.1007/s10620-025-09603-w. doi:10.1007/s10620-025-09603-w.
21. The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development. Genua F, Raghunathan V, Jenab M, Gallagher WM, Hughes DJ. Frontiers in Oncology. 2021;11:626349. doi:10.3389/fonc.2021.626349.
22. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. Kinashi Y, Hase K. Frontiers in Immunology. 2021;12:673708. doi:10.3389/fimmu.2021.673708.
23. Leaky Gut as a Danger Signal for Autoimmune Diseases. Mu Q, Kirby J, Reilly CM, Luo XM. Frontiers in Immunology. 2017;8:598. doi:10.3389/fimmu.2017.00598.
24. The Role of Intestinal Mucosal Barrier in Autoimmune Disease: A Potential Target. An J, Liu Y, Wang Y, et al. Frontiers in Immunology. 2022;13:871713. doi:10.3389/fimmu.2022.871713.
25. Gut Microbiota, Leaky Gut, and Autoimmune Diseases. Christovich A, Luo XM. Frontiers in Immunology. 2022;13:946248. doi:10.3389/fimmu.2022.946248.
26. Increased Gut Permeability and Bacterial Translocation Are Associated With Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Disease-Related Biomarker Discovery. Martín F, Blanco-Suárez M, Zambrano P, et al. Frontiers in Immunology. 2023;14:1253121. doi:10.3389/fimmu.2023.1253121.
27. The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). König RS, Albrich WC, Kahlert CR, et al. Frontiers in Immunology. 2021;12:628741. doi:10.3389/fimmu.2021.628741.
28. Physical Capacity Modulates Intestinal Barrier Dysfunction in Functional Disorders: Phenotype-Specific Patterns in Fibromyalgia and Irritable Bowel Syndrome. Russo F, Bianco A, Prospero L, et al. Frontiers in Physiology. 2025;16:1695163. doi:10.3389/fphys.2025.1695163.
29. The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes With an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome. Morris G, Berk M, Carvalho AF, et al. Current Pharmaceutical Design. 2016;22(40):6058-6075. doi:10.2174/1381612822666160914182822.
30. Increased Intestinal Mucosal Permeability and Metabolic Endotoxemia Predict the Risk of Cardiovascular Mortality. Parantainen J, Barreto G, Strandberg TE, et al. Atherosclerosis. 2025;405:119220. doi:10.1016/j.atherosclerosis.2025.119220.
31. IL-6, IL-10, sFas, Granulysin and Indicators of Intestinal Permeability as Early Biomarkers for a Fatal Outcome in COVID-19. Hernández-Solis A, Güemes-González AM, Ruiz-Gómez X, et al. Immunobiology. 2022;227(6):152288. doi:10.1016/j.imbio.2022.152288.
32. Human Intestinal Barrier: Effects of Stressors, Diet, Prebiotics, and Probiotics. Camilleri M. Clinical and Translational Gastroenterology. 2021;12(1):e00308. doi:10.14309/ctg.0000000000000308.
33. Perspective: Prospects for Nutraceutical Support of Intestinal Barrier Function. McCarty MF, Lerner A. Advances in Nutrition (Bethesda, Md.). 2021;12(2):316-324. doi:10.1093/advances/nmaa139.
34. Advances in Dietary Modulation of the Intestinal Barrier: Mechanistic, Structural, and Functional Insights. Zang J, Xiao L, Shi Y, et al. Comprehensive Reviews in Food Science and Food Safety. 2026;25(1):e70383. doi:10.1111/1541-4337.70383.
35. Macronutrients as Regulators of Intestinal Epithelial Permeability: Where Do We Stand?. Martínez-Augustin O, Tena-Garitaonaindia M, Ceacero-Heras D, et al. Comprehensive Reviews in Food Science and Food Safety. 2025;24(3):e70178. doi:10.1111/1541-4337.70178.
36. Popular Dietary Patterns: Alignment With American Heart Association 2021 Dietary Guidance: A Scientific Statement From the American Heart Association. Gardner CD, Vadiveloo MK, Petersen KS, et al. Circulation. 2023;147(22):1715-1730. doi:10.1161/CIR.0000000000001146.
37. Popular Fad Diets: An Evidence-Based Perspective. Anderson K. Progress in Cardiovascular Diseases. 2023 Mar-Apr;77:78-85. doi:10.1016/j.pcad.2023.02.001.
38. A Clinician's Guide for Trending Cardiovascular Nutrition Controversies: Part II. Freeman AM, Morris PB, Aspry K, et al. Journal of the American College of Cardiology. 2018;72(5):553-568. doi:10.1016/j.jacc.2018.05.030.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.